Canaccord Genuity analyst Arlinda Lee maintained a Buy rating on Nektar Therapeutics (NKTR) yesterday and set a price target of $25.00. The company’s shares closed last Tuesday at $19.48.
According to TipRanks.com, Lee is a 3-star analyst with an average return of 1.1% and a 44.5% success rate. Lee covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Black Diamond Therapeutics, and Deciphera Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nektar Therapeutics with a $27.67 average price target, a 41.9% upside from current levels. In a report issued on April 22, Benchmark Co. also initiated coverage with a Buy rating on the stock with a $26.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $36.85 and a one-year low of $13.64. Currently, Nektar Therapeutics has an average volume of 1.51M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
